Pre-Made Inbakicept biosimilar, Fusion Protein: Recombinant therapeutic protein targeting IL15 fused with human IGHG1 Fc (Fragment constant) for drug discovery and mechanism of action (MOA) research

Pre-Made Inbakicept biosimilar, Fusion Protein: Recombinant therapeutic protein targeting IL15 fused with human IGHG1 Fc (Fragment constant) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Inbakicept is a human IL-15 superagonist with immunostimulatory properties with promising anti-cancer treatment and it is also being investigated as an HIV treatment. Inbakicept is a soluble complex consisting of two protein subunits of a human interleukin (IL)-15 variant (nogapendekin alfa) bound with high affinity to a dimeric human IL-15 receptor α (IL-15 Rα) sushi domain/human IgG1 Fc fusion protein. This fusion protein has been designed to simulate the normal mechanism of action of IL-15 where IL-15 and IL-15 Rα are coordinately expressed by antigen-presenting cells (monocytes and dendritic cells) and presented in trans to neighboring NK cells or CD8 + T cells expressing the CD122/CD132 receptor complex.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-864-1mg	1mg	3090
GMP-Bios-INN-864-10mg	10mg	Inquiry
GMP-Bios-INN-864-100mg	100mg	Inquiry
GMP-Bios-INN-864-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Inbakicept biosimilar, Fusion Protein: Recombinant therapeutic protein targeting IL15 fused with human IGHG1 Fc (Fragment constant)
INN Name	Inbakicept
Target	IL15
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - [IL15RA (interleukin 15 receptor subunit alpha, CD215, IL- 15RA)]2 - IGHG1 Fc (Fragment constant)
VD LC	Fusion - [IL15RA (interleukin 15 receptor subunit alpha, CD215, IL- 15RA)]2 - IGHG1 Fc (Fragment constant)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Altor BioScience (FL USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0